Although this study focused on grade 3 tumors, it suggests that PCV may offer superior survival outcomes compared to TMZ in IDH-mutant, 1p/19q-codeleted gliomas, potentially informing treatment decisions for grade 2 oligodendrogliomas as well. This evidence concerns the gene IDH2 and oligodendroglioma.